<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504437</url>
  </required_header>
  <id_info>
    <org_study_id>BMMSC-1</org_study_id>
    <nct_id>NCT02504437</nct_id>
  </id_info>
  <brief_title>Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease</brief_title>
  <acronym>TPAABPIHD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Academy Military Medical Science, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academy Military Medical Science, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the efficacy of the preconditioned autologous
      bone marrow mesenchymal stem cells for patients with ischemic heart diseases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LVEF (left ventricular ejection fraction)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>pre-conditioned BMMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMMSCs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMMSCs</intervention_name>
    <arm_group_label>pre-conditioned BMMSCs</arm_group_label>
    <arm_group_label>BMMSCs</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age under 75;

          -  Clinical diagnosis of acute Myocardial Infarction, chronic Myocardial Infarction and
             Ischemic Cardiomyopathy

          -  NYHA (New York Heart Association) grade: III-IV, LVEF (left ventricular ejection
             fraction): 25-50%;

          -  No infection diseases including HBV (hepatitis B virus), HCV (hepatitis C virus ),
             syphilis and AIDS;

          -  No psychiatric illnesses and speaking dysfunction;

          -  Informed consent.

        Exclusion Criteria:

          -  More than 75 years old;

          -  LVEF&lt;24%;

          -  Unstable hemodynamics, shock;

          -  Severe infection;

          -  Patients have tumor or other lethal diseases (expectation of life&lt;6 months);

          -  Radiation patients;

          -  hematopoietic malignancy including Haemophiliacs;

          -  Anemia (Hb&lt;100g/L);

          -  The other clinical trial participants within one month;

          -  Abnormal increasing of the blood biochemical indicators that is not explained by the
             conditions;

          -  Informed refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuetao Pei, M.D., Ph.D</last_name>
    <phone>8610-68164807</phone>
    <email>AMMS0906@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junnian Zhou, Ph.D</last_name>
    <phone>8620-89199011</phone>
    <email>zhoujunnian@scrm.org.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Gao LR, Pei XT, Ding QA, Chen Y, Zhang NK, Chen HY, Wang ZG, Wang YF, Zhu ZM, Li TC, Liu HL, Tong ZC, Yang Y, Nan X, Guo F, Shen JL, Shen YH, Zhang JJ, Fei YX, Xu HT, Wang LH, Tian HT, Liu DQ, Yang Y. A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol. 2013 Oct 9;168(4):3191-9. doi: 10.1016/j.ijcard.2013.04.112. Epub 2013 May 4.</citation>
    <PMID>23651816</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academy Military Medical Science, China</investigator_affiliation>
    <investigator_full_name>Xuetao Pei</investigator_full_name>
    <investigator_title>Director, Head of South China Research Center for Stem Cell &amp; Regenerative Medicine, AMMS, Guangzhou, China.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

